735 related articles for article (PubMed ID: 25947646)
1. VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis.
Santos LV; Cruz MR; Lopes Gde L; Lima JP
Breast Cancer Res Treat; 2015 Jun; 151(3):481-9. PubMed ID: 25947646
[TBL] [Abstract][Full Text] [Related]
2. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner AD; Thomssen C; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
[TBL] [Abstract][Full Text] [Related]
3. Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.
Pentheroudakis G; Kotoula V; Kouvatseas G; Charalambous E; Dionysopoulos D; Zagouri F; Koutras A; Papazisis K; Pectasides D; Samantas E; Dimopoulos MA; Papandreou CN; Fountzilas G
Clin Breast Cancer; 2014 Oct; 14(5):330-8. PubMed ID: 24703319
[TBL] [Abstract][Full Text] [Related]
4. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
[TBL] [Abstract][Full Text] [Related]
5. Anti-angiogenic therapies for metastatic colorectal cancer.
Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.
Valachis A; Polyzos NP; Patsopoulos NA; Georgoulias V; Mavroudis D; Mauri D
Breast Cancer Res Treat; 2010 Jul; 122(1):1-7. PubMed ID: 20063120
[TBL] [Abstract][Full Text] [Related]
7. Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses.
Bais C; Mueller B; Brady MF; Mannel RS; Burger RA; Wei W; Marien KM; Kockx MM; Husain A; Birrer MJ;
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059426
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: pros and cons.
Sini V; Cassano A; Corsi D; De Laurentiis M; Gamucci T; Mauri M; Naso G; Roselli M; Ruggeri EM; Tonini G; Vici P; Zampa G; Marchetti P
Tumori; 2016 Oct; 102(5):472-480. PubMed ID: 27647231
[TBL] [Abstract][Full Text] [Related]
9. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
10. Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials.
Li J; Zhou L; Chen X; Ba Y
Clin Transl Oncol; 2015 Sep; 17(9):673-83. PubMed ID: 25990506
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.
Cameron D; Brown J; Dent R; Jackisch C; Mackey J; Pivot X; Steger GG; Suter TM; Toi M; Parmar M; Laeufle R; Im YH; Romieu G; Harvey V; Lipatov O; Pienkowski T; Cottu P; Chan A; Im SA; Hall PS; Bubuteishvili-Pacaud L; Henschel V; Deurloo RJ; Pallaud C; Bell R
Lancet Oncol; 2013 Sep; 14(10):933-42. PubMed ID: 23932548
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
Wu YS; Shui L; Shen D; Chen X
Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
[TBL] [Abstract][Full Text] [Related]
13. Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis.
Ciccarese C; Iacovelli R; Bria E; Mosillo C; Bimbatti D; Fantinel E; Bisogno I; Brunelli M; Tortora G
Semin Oncol; 2019 Feb; 46(1):65-72. PubMed ID: 30665685
[TBL] [Abstract][Full Text] [Related]
14. Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer.
Slaughter KN; Thai T; Penaroza S; Benbrook DM; Thavathiru E; Ding K; Nelson T; McMeekin DS; Moore KN
Gynecol Oncol; 2014 Apr; 133(1):11-5. PubMed ID: 24680585
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic Therapy in Advanced Non-small-cell Lung Cancer: A Meta-analysis of Phase III Randomized Trials.
Raphael J; Chan K; Karim S; Kerbel R; Lam H; Santos KD; Saluja R; Verma S
Clin Lung Cancer; 2017 Jul; 18(4):345-353.e5. PubMed ID: 28188101
[TBL] [Abstract][Full Text] [Related]
16. The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials.
Roviello G; Bachelot T; Hudis CA; Curigliano G; Reynolds AR; Petrioli R; Generali D
Eur J Cancer; 2017 Apr; 75():245-258. PubMed ID: 28242502
[TBL] [Abstract][Full Text] [Related]
17. Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials.
Li Y; Liang XY; Yue YQ; Sheng L; Liu JK; Wang ZY; Chen G
Tumour Biol; 2016 May; 37(5):6297-306. PubMed ID: 26619847
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab in combination with first-line chemotherapy in patients with metastatic colorectal cancer: a meta-analysis.
Hu W; Xu WS; Liao XF; He HJ
Minerva Chir; 2015 Dec; 70(6):451-8. PubMed ID: 26013763
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.
Van Cutsem E; de Haas S; Kang YK; Ohtsu A; Tebbutt NC; Ming Xu J; Peng Yong W; Langer B; Delmar P; Scherer SJ; Shah MA
J Clin Oncol; 2012 Jun; 30(17):2119-27. PubMed ID: 22565005
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.
Miles D; Cameron D; Bondarenko I; Manzyuk L; Alcedo JC; Lopez RI; Im SA; Canon JL; Shparyk Y; Yardley DA; Masuda N; Ro J; Denduluri N; Hubeaux S; Quah C; Bais C; O'Shaughnessy J
Eur J Cancer; 2017 Jan; 70():146-155. PubMed ID: 27817944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
